We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+46.74%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.57B
AUM Growth
+$1.21B
Cap. Flow
-$9.19M
Cap. Flow %
-0.26%
Top 10 Hldgs %
45.04%
Holding
142
New
39
Increased
22
Reduced
59
Closed
10

Top Buys

Rank Stock Value
1
GDS icon
GDS Holdings
GDS
+$68.1M
2
GBIO
Generation Bio
GBIO
+$62.7M
3
RPRX icon
Royalty Pharma
RPRX
+$37.1M
4
ONC
BeOne Medicines Ltd
ONC
+$32.6M
5
NG icon
NovaGold Resources
NG
+$26.3M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$137M
2
AVTR icon
Avantor
AVTR
+$40.7M
3
PYPL icon
PayPal
PYPL
+$33.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$27M
5
Z icon
Zillow
Z
+$20.7M

Sector Composition

Rank Sector Weight
1 Healthcare 62.42%
2 Miscellaneous 17.82%
3 Consumer Discretionary 13.38%
4 Technology 3.16%
5 Financials 1.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRIS icon
126
Curis
CRIS
$2.74M
$1.79M 0.05%
3,697
-53
-1% -$19.5K
VXRT
127
DELISTED
Vaxart
VXRT
$1.77M 0.05%
+200,000
New +$575K
CTMX icon
128
CytomX Therapeutics
CTMX
$586M
$1.57M 0.04%
+188,000
New +$1.75M
BLU
129
DELISTED
BELLUS Health Inc.
BLU
$1.48M 0.04%
+143,763
New +$1.46M
IRWD icon
130
Ironwood Pharmaceuticals
IRWD
$671M
$1.14M 0.03%
110,532
– –
CDTX
131
DELISTED
Cidara Therapeutics
CDTX
$873K 0.02%
+11,825
New +$766K
RIGL icon
132
Rigel Pharmaceuticals
RIGL
$829M
$619K 0.02%
33,800
-1,200
-3% -$21.6K
ARWR icon
133
Arrowhead Research
ARWR
$9.98B
– –
-600,000
Closed -$17.3M
BABA icon
134
CALL
Alibaba
BABA
$272B
– –
-400,000
Closed -$77.8M
BLUE
135
DELISTED
bluebird bio
BLUE
– –
-7,720
Closed -$4.6M
BMRN icon
136
CALL
BioMarin Pharmaceuticals
BMRN
$12.5B
– –
-200,000
Closed -$16.9M
BPMC
137
CALL
DELISTED
Blueprint Medicines
BPMC
– –
-200,000
Closed -$11.7M
MA icon
138
CALL
Mastercard
MA
$502B
– –
-100,000
Closed -$24.2M
UBER icon
139
Uber
UBER
$146B
– –
-400,000
Closed -$11.2M
XBI icon
140
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-500,000
Closed -$38.7M
CLVS
141
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-1,000,000
Closed -$7.57M
PTLA
142
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-200,000
Closed -$1.43M
2 3 4 5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2020 Portfolio in Review

As of Q2 2020, Artal Group held 142 positions worth $3.57B, up 51% from $2.37B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Artal Group's Q2 2020 filing shows 39 new, 22 increased, 59 reduced and 10 closed positions. Its largest new stake was GDS Holdings: 1,100,000 shares worth $87.6M. The largest sale was Moderna, an estimated $137M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 69% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

  • Artal Group's largest Q2 2020 buy was GDS Holdings: 1,100,000 shares worth $87.6M.
  • Artal Group added most to BeOne Medicines Ltd in Q2 2020, an estimated $32.6M increase.
  • Artal Group's biggest Q2 2020 reduction was Moderna, cutting an estimated $137M.
  • Artal Group fully exited Arrowhead Research in Q2 2020, selling an estimated $17.3M.
  • Artal Group's ten largest holdings make up 45% of its $3.57B portfolio in Q2 2020.
  • Artal Group opened 39 new positions and closed 10 in Q2 2020.
  • Artal Group's portfolio value rose 51% quarter-over-quarter to $3.57B.

Based on Artal Group's 13F filing for Q2 2020, filed 14 Aug 2020.